Johnson & Johnson: A Bullish Stock Amid Market Volatility

Johnson & Johnson's stock is considered a "textbook slowdown stock" by Jim Cramer, but he believes it's a buying opportunity due to FDA approval for an oral treatment for moderate to severe plaque psoriasis. The company develops and sells healthcare products, including pharmaceuticals and medical technologies, in various treatment areas. However, certain AI stocks offer greater upside potential and carry less downside risk.